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Targeted cancer exome sequencing reveals recurrent mutations
in myeloproliferative neoplasms
E Tenedini1,2,3, I Bernardis1,2, V Artusi1,2, L Artuso1,2, E Roncaglia1,2, P Guglielmelli4, L Pieri4, C Bogani4, F Biamonte4, G Rotunno4,
C Mannarelli4, E Bianchi2,3, A Pancrazzi4, T Fanelli4, G Malagoli Tagliazucchi1,2, S Ferrari1,2, R Manfredini2,3, AM Vannucchi4 and
E Tagliafico1,2 on behalf of AGIMM investigators
With the intent of dissecting the molecular complexity of Philadelphia-negative myeloproliferative neoplasms (MPN), we designed a
target enrichment panel to explore, using next-generation sequencing (NGS), the mutational status of an extensive list of 2000 cancer-
associated genes and microRNAs. The genomic DNA of granulocytes and in vitro-expanded CD3þ T-lymphocytes, as a germline control,
was target-enriched and sequenced in a learning cohort of 20 MPN patients using Roche 454 technology. We identiﬁed 141 genuine
somatic mutations, most of which were not previously described. To test the frequency of the identiﬁed variants, a larger validation
cohort of 189 MPN patients was additionally screened for these mutations using Ion Torrent AmpliSeq NGS. Excluding the genes
already described in MPN, for 8 genes (SCRIB, MIR662, BARD1, TCF12, FAT4, DAP3, POLG and NRAS), we demonstrated a mutation
frequency between 3 and 8%. We also found that mutations at codon 12 of NRAS (NRASG12V and NRASG12D) were signiﬁcantly
associated, for primary myeloﬁbrosis (PMF), with highest dynamic international prognostic scoring system (DIPSS)-plus score categories.
This association was then conﬁrmed in 66 additional PMF patients composing a ﬁnal dataset of 168 PMF showing a NRAS mutation
frequency of 4.7%, which was associated with a worse outcome, as deﬁned by the DIPSS plus score.
Leukemia (2014) 28, 1052–1059; doi:10.1038/leu.2013.302
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INTRODUCTION
The discovery of the JAK2V617F mutation in 20051 represented a
major breakthrough in the understanding of the molecular
pathogenesis of Philadelphia chromosome-negative chronic
myeloproliferative neoplasms (MPN).2 The JAK2V617F mutation
is harbored by nearly all polycythemia vera (PV) patients and 50–
60% of patients with essential thrombocythemia (ET) and primary
myeloﬁbrosis (PMF).3 The resulting constitutively activated JAK/
STAT signaling is considered central to the pathogenesis4 and
phenotype of MPN and therefore serves as a rational drug target
for therapy.5 Additional mutations were described at MPL codon
10 (W515L/K/A) in 5–8% of ET and PMF patients.6–8 However, the
signiﬁcant proportion of JAK2V617F- and MPLW515L-negative
MPN cases required additional effort to identify novel genetic
lesions contributing to disease pathogenesis. Recent studies based
on single-nucleotide polymorphism (SNP) array-based karyotyping
resulted in the detection of several copy number alterations
such as a loss of heterozygosity and a copy neutral loss of
heterozygosity in genomic regions containing multiple members
of the polycomb repressive complex 29–12 and other genes
previously implicated in different hematological malignancies.13
Moreover, via candidate gene sequencing, several novel bona ﬁde
somatic mutations14 were detected at frequencies ranging from
1% to 20–30% in genes frequently mutated in other myeloid
neoplasms, as well as MDS and acute myeloid leukemia, and some
of these mutations have been positively correlated with clinical
outcome.15–18 Nevertheless, because a signiﬁcant proportion
of MPN cases are negative for molecular aberrations, a complete
portrait of MPN genetic abnormalities remains to be depicted.
The two major theoretical and technical drawbacks to the identi-
ﬁcation of new somatic mutations are represented, respectively,
by the huge number of genes potentially involved in MPN
tumorigenesis and by the availability of ‘pure’ germline control
DNA. Buccal swabs and saliva have generally been considered as
readily available sources of non-hematopoietic DNA, but detection
of the JAK2V617F mutation in at least some of these samples
suggested the presence of myeloid cell contamination.
In addition, no evidence for germline transmission of the
JAK2V617F mutation has been elucidated until now.
Given these previous results and with the goal of further
exploring the molecular complexity of MPN, we investigated the
incidence of mutations in genes already known to be implicated in
cancer pathogenesis. Therefore, we designed a two-tiered next-
generation sequencing (NGS) study. We ﬁrst evaluated the somatic
mutational status of a mostly inclusive list of known cancer-related
genes in a 25 MPN sample learning set. We then tested the
recurrence of the truly somatic variants in a broader validation set of
189 patients via an amplicon-sequencing NGS approach.
MATERIALS AND METHODS
Patients and samples
Patients were diagnosed as having PV, PMF and post PV-MF according to
the World Health Organization (WHO)19 and the International Working
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Group for Myeloﬁbrosis Research and Treatment (IWG-MRT) criteria.20
All subjects provided informed written consent, and the study was
performed under the Florence Institutional Review Board’s approved
protocol. The study was conducted in accordance with the Declaration of
Helsinki. The presence of the JAK2V617F and MPLW515L mutations
and the mutated allele burden were determined via quantitative real-
time PCR (QRT–PCR), as previously described.21
The mutational status of ASXL1, EZH2, IDH1, as well as IDH2, SRSF2, TET2,
DNMT3A and CBL was assessed using Sanger sequencing, as previously
described.18 Cytogenetic analysis was performed on Giemsa-stained slides.
All patients were examined within 1 year of diagnosis.
Granulocyte and CD3þ T cell puriﬁcation and genomic DNA
extraction
Granulocytes were obtained via the density gradient centrifugation of
peripheral blood samples, and CD3þ cells were immunomagnetically
selected (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) from
the peripheral blood mononuclear cell fraction recovered from the
density gradient. After sorting, CD3þ cells were expanded in vitro. The
purity of the CD3þ cells was determined using ﬂow cytometry. The
culture conditions as well the DNA extraction quality control procedures
are fully described in the Materials and Methods section of the
Supplementary Information.
Target enrichment and 454 sequencing
A solution-based capture custom panel was designed for target enrich-
ment according to the NimbleGen (Roche NimbleGen, Inc., Madison,
WI, USA) guidelines. The ﬁnal list of genes and miRNAs were obtained by
combining the complete list of mutations present in the latest release of
the Sanger Institute Cancer Gene Census Database (www.sanger.ac.uk/
genetics/CGP/Census) with the most inclusive list of DNA repair genes
present in the OMIM Database (www.ncbi.nlm.nih.gov/omim) as well as a
manually curated literature screening. The custom design was inserted into
a 5-Mb SeqCap EZ Choice Library (Roche NimbleGen, Inc., Madison, WI,
USA) containing the exonic portions of 1400 genes and 600 miRNA coding
sequences (Supplementary Table 1).
A sample library preparation was performed using 500 ng of DNA from
the granulocyte and CD3þ T-cell samples. Each step of the working
procedure to perform sequencing runs on the Roche 454 GS FLX platform
is fully described in the Materials and Methods section of the
Supplementary Information.
Variant detection, ﬁltering and classiﬁcation
The processing of the samples, evaluation of genuine somatic mutations
and their classiﬁcation are entirely described in the Materials and Methods
section of the Supplementary Information.
Recurring variant validation test
Recurrence testing for genuine somatic variants was performed using Ion
AmpliSeq technology with an Ion Torrent Personal Genome Machine
(PGM) platform. The Ion AmpliSeq panel design, sample processing,
barcoding and sequencing are fully described in the Materials and
Methods section of the Supplementary Information.
N-RAS c.35 G4A mutation analysis
An independent set of 139 patients with PMF were recruited from the
archive in Florence and used for NRAS and KRAS mutation analysis
(see Materials and Methods section of the Supplementary Information for
details).
Statistical analysis
The w2, Fisher’s exact test (2 2 table) or w2 test for trend (larger
contingency table) were used as appropriate to compare variables from
different patient groups that had been categorized according to
mutational status. The analysis of continuous variables among the groups
was performed using the Mann-Whitney U test (two groups) or the
Kruskal–Wallis test with the Dunn method for multiple comparisons.
Po0.05 was considered to indicate statistical signiﬁcance; all tests
were two-tailed. Data were processed using SPSS Version 19.0 software
(StatSoft, Tulsa, OK, USA).
RESULTS
A total of 25 tumor granulocyte and paired germline samples
comprised the learning cohort. The NGS samples had been
collected at the time of diagnosis in 9 PV subjects and 11 PMF
subjects, while the additional 5 DNA samples were obtained from
5 of the 9 PV patients at the time that they evolved to post-PV
myeloﬁbrosis.
The learning cohort for PMF was deliberately selected as
being predominantly JAK2V617F-negative (9/11 subjects), with
only 2 JAK2V617F-positive patients. The stratiﬁcation of patients
according to the dynamic international prognostic scoring system
(DIPSS)22 and other clinical features of the cohort are summarized
in Supplementary Table 2.
Identiﬁcation of genuine somatic mutations in coding sequences
and microRNAs
According to the NimbleGen procedure, the tumor granulocytic,
germline salivary and CD3þ lymphocytic gDNA samples were
sheared, barcoded and mixed in an appropriate number of
template libraries that were subsequently captured. At the end of
the gDNA sequence selection procedure, all the DNA libraries
were checked using QRT–PCR to verify the relative fold enrich-
ment of the panel; all libraries produced a fully satisfactory result
and conﬁrmed successful captures (data not shown). Next, each
library was sequenced with 454 Titanium technology using the
Roche GS FLX platform. To exclude unbalanced libraries, that is,
libraries composed of a nonequimolar quantity of the samples, we
checked for any possible unequal sequencing depth in the
barcoded samples. As exempliﬁed for the library shown in
Supplementary Figure 1, balanced quantities of samples were
pooled, captured and then processed.
DNA libraries were sequenced until the median 30-fold cover-
age was reached for each tumor or control sample. A very high
capture speciﬁcity was observed (94% of unique reads in the
target region) with a similar uniformity throughout the chromo-
somes (average standard deviation assessed to 1.6) (Figure 1).
Genuine germline sample selection
To identify somatic mutations in the MPN learning dataset, we
sequenced paired DNA samples from granulocytes and germline
cells. The candidate mutations detected in the granulocytes were
then screened by subtracting those occurring in the germline to
enable the identiﬁcation of the variants that could be reliably
considered truly acquired somatic variants.
In the ﬁrst set of experiments, we employed DNA obtained from
paired saliva samples, but this DNA consistently presented
variants belonging to the neoplastic clone, notably the JAK2V617F
mutation, with a comparable allele burden. These results
prompted us to consider that saliva samples could not be
considered genuine germline sources due to contamination by
myeloid cells. Thus, we replicated the experiments using
expanded CD3þ T cell DNA for control samples, and a very low
level of somatic contamination was found in just 1 DNA sample
from CD3þ T cells. Table 1 displays the mutational burden
comparison for JAK2, MPL and IDH2 in libraries prepared from
different sources of DNA (granulocytes, saliva and CD3þ T cells).
As a result, we discarded the data obtained from the salivary
samples and selected for further analyses only those obtained
from CD3þ T cells, which were deﬁnitively considered germline
control samples.
Somatic mutations identiﬁcation in genes and microRNAs in
the learning cohort
The tumor and paired germline sample data were both mapped
against the human reference genome (hg19). A total of 11006 and
9691 unique variants in 1057 and 1039 genes for the germline and
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somatic samples, respectively, were detected, as shown in
Supplementary Table 3.
The somatic variant identiﬁcation procedure was intended to
minimize the false positive somatic mutation rate. To this end, we
used a two-step stringent approach. First, using a ‘somatic’ ﬁlter,
we selected only DNA variants in tumor samples with no mutated
reads either in the paired germline counterpart or in any other
germline samples of the cohort. A ‘functional’ ﬁlter was then
applied to eliminate the synonymous variants and all variants
annotated in the 1000 Genomes database as having a frequency
higher than 1% (see Materials and Methods for details).
Supplementary Table 3 summarizes the narrowing of the unique
detected variants after each of the analysis steps described above.
Then, for evaluating for possible sequencing errors and the false
positive rate, we validated these variants using a different type of
NGS technology; speciﬁcally, we designed an Ion AmpliSeq
panel containing all detected variants that was employed to
re-sequence the same patient cohort via Ion Torrent PGM
(1000-fold coverage).
Using this strategy, we estimated a very low sequencing
error rate (o1%), and we ﬁnally conﬁrmed 136 genuine somatic,
non-synonymous mutations affecting 121 genes. Twenty-ﬁve
percent of these mutations are indexed in the dbSNP archive,
and 2% of these speciﬁc variants are listed in COSMIC catalogue.
The majority of mutations (89%) were estimated to be ‘damaging’
by at least 1 of the 5 algorithms that we used to investigate
disease-causing potential (PolyPhen2, SIFT, Provean, Mutation
Taster, LTR) (Supplementary Table 4 and Figure 2).
The vast majority of the identiﬁed somatic mutations were
missense (92%), whereas the minority (8%) were indels (small
insertions and deletions). Despite patients harboring different
numbers of somatic mutations spanning from 1 to 21 variants
(Table 2), only 14 genes appeared to be recurrently mutated
(Figure 3) in at least two patients. It should be noted that the
acquisition of additional mutations and/or the occurrence of loss
of some mutations at the time of disease evolution from PV to
post-PV myeloﬁbrosis in patients for whom samples were
available at both disease phases suggested the occurrence of
sub-clone selection during disease evolution (Supplementary
Table 5).
Five missense variants were identiﬁed in the 600 microRNAs
coding sequences tested. These missense variants are summarized
in Table 3. The MIR662, MIR663 and MIR542 sequences harbored
missense mutations in their stem-loop coding region, and the
MIR17 mutation was shown to affect the miR-17-5p mature miRNA
sequence 5 bases downstream of its seed region.
Somatic mutation recurrence in the validation cohort
To distinguish between the identiﬁed somatic variants and
possible novel clonal drivers from clonal passenger mutations,
we tested the recurrence of the above-described variants in a
broader cohort of 189 patients diagnosed with PMF (91 samples,
48.2%), PV (50 patients, 26.4%) or post-PV myeloﬁbrosis (48
samples, 25.4%). We utilized the Ion AmpliSeq panel and PGM
sequencing as previously described to obtain an ultra-deep
amplicon sequencing (see Supplementary Information for techni-
cal details) of the 141 variants, achieving a sample median of
1000-fold coverage. The clinical parameters of the patients
comprising the validation set are summarized in Supplementary
Table 2.
Excluding the JAK2, MPL, IDH2, ASXL1, TET2, CBL and DNMT3A
known variants, 80 patients (42% of total) harbored at least 1 of
the 141 somatic mutations tested for recurrence. Thirty somatic
mutations (18.9% of the total) were displayed in at least 1 of the
189 patients; these were all missense mutations with the
exception of a single frameshift mutation occurring in the BRD4
gene (Table 4).
Figure 1. Enrichment uniformity landscape. The X-axis graphs the
number of target regions included in the NimbleGen capture ‘cancer
exome’ panel (approximately 29600 target regions in total).
The light bars represent the number of target regions within the
design, whereas the dark bars correspond to the effective number of
enriched target regions for each chromosome. The Y-axis displays
the chromosomes.
Table 1. Comparison of allele burden for selected mutations in
libraries prepared from different DNA sources
Patient Granulocytes CD3þ
T cells
Salivary
samples
JAK2 V617F
PV_4 64% 0% 67%
PMF_2 76% 0% 58%
PV_9–PPV_5 96–83% 0% 87%
PV_3 62% 0% 78%
PV_6–PPV_2 67–100% 14% 93%
IDH2 R140Q
PMF_9 55% 0% 37%
MPL W515L
PMF_9 80% 0% 38%
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In addition, 8 genes (SCRIB, MIR662, BARD1, TCF12, FAT4, DAP3,
POLG and NRAS) appeared as recurrently mutated in the cohort,
some of which (SCRIB 7.9%, MIR662 7.4% and BARD1 5.3%) were
more frequently mutated than previously identiﬁed, well-known
mutational hotspots18 (Table 4).
Correlations between recurrent mutations and clinical features:
NRAS c.35 G4A mutation analysis
The groupwise associations between recurrent mutations
and clinical and biological features were assessed using the w2
test or Fisher’s exact test. Possibly because of the small number
of subjects harboring each unique mutation abnormality, no
signiﬁcant association with clinical features was found, with the
exception of mutations at codon 12 of NRAS (NRASG12V and
NRASG12D) that occurred in 5 out 102 PMF patients included in
the learning and validation cohorts. This association resulted in
P-valueso0.05 for the highest DIPSS-plus score categories. DIPPS-
plus23 effectively combines prognostic information from the DIPSS
with karyotype, platelet count, and transfusion status to predict
overall survival in PMF. This evidence prompted us to screen the
NRAS gene for mutations in codon 12 in an independent cohort of
66 PMF patients via high-resolution melting analysis followed by
Sanger sequencing validation, ﬁnding an additional 3 mutated
subjects. Moreover, because NRAS and KRAS mutations have been
described as possibly mutually exclusive, we also tested this
cohort for KRAS mutations. As a whole, we found 8 of 168 MF
patients (4.7%) harboring a heterozygous NRAS mutation in codon
Figure 2. Circular diagram of mutations found in MPN. Chromosomes are illustrated in the outer perimeter. Grey dots show the ‘cancer exome’
regions of the NimbleGen panel, whereas the histograms show the captured (blue) and failed (red) target regions. MicroRNA or Gene Symbol
with amino acidic change refers to the variants found in our cohort.
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12 (5 harbored the NRASG12V mutation and 3 harbored the
NRASG12D mutation). In addition, 3 patients of 168 evaluated
(1.6%) harbored heterozygous KRAS mutations (G12R, G12S,
and G13D); the patient carrying the KRASG13D mutation also
harbored the NRASG12V variant. Of note, NRAS variants
preferentially clustered among JAK2 wild-type subjects since
only 1 of 8 mutated NRAS patients also harbored the JAK2V617F.
Finally, we conﬁrmed a signiﬁcant association of NRAS variants
with DIPSS-plus scoring (P¼ 0.022) since all the 8 mutated
patients were included in the highest (intermediate-2 and high)
risk category, as shown in Table 5.
DISCUSSION
The discovery of the JAK2V617F mutation represents the
single most signiﬁcant contribution to the characterization of
the pathophysiology of MPN thus far and has major implications
also for the treatment of these malignancies. Mutations char-
acterizing genes other than JAK2 involve less than the 20% of MPN
patients and often are co-expressed with the JAK2 mutation; thus,
even though the impact of the mutational status of a speciﬁc set
of genes (ASXL1, EZH2, SRSF2 and IDH) on disease outcome
has been demonstrated in patients with PMF,18 a comprehensive
molecular landscape of MPN has not yet been completely
depicted. Here, we performed the ﬁrst large targeted
NGS analysis aimed at exploring the mutational status of the
broadest panel of known cancer-associated genes in MPN. This is
the ﬁrst report describing a robust NGS study design and an
accurate data analysis pipeline aimed at minimizing the somatic
mutation false positive rate. We also demonstrated that saliva
samples are often heavily contaminated by myeloid cells and that
expanded CD3þ T cells in culture therefore serve as the most
Table 2. Number of genuine somatic, non-synonymous mutations harboured by each patient. Variants in MPN known mutated genes are shown in
bold
Disease_#
patient
number
Number of
somatic
mutations
PMF_1 4 FIP1L1D183G, JAK2V617F, PRPF19L341P, TPRN1790D
PMF_2 6 APCR2126G, BRCA1R163G, BRCA2K1690N, CTNNA1P735L, GAS8L126P, JAK2V617F
PMF_3 7 APLFR510fsX3, BRIP1L456P, DLGAP2R134K, ERBB2L494F, FANCMR756C, MPGR55C, RECQL4P879H
PMF_4 5 DNMT3AR693C, IRF4T361A, PLCD1R476C, PTPRFE1245K, ZFHX3K3243R
PMF_5 3 EME1Q556X, RABEP1E550G, SEPT6V168A
PMF_6 5 BARD1C557S, PER1L214F, SEZ6LT1014A, SEZ6LT381N, SYKV560A
PMF_7 10 ACSL6A52V, AIFM2G2V, AKT1W99R, ATRG1362E, CARSQ253R, IRF4R201H, RNF6R75W, TP53G245D, TP73E634K,
TRHR83H
PMF_8 7 CDC25AC159Y, EPS15Q365R, FAT1E3812G, MPLW515L, NRASG12V, RFWD2M299V, TCF12G300S
PMF_9 10 ASXL1K825X, DAB2IPN230D, FAT2T858I, HIF1AW316R, IDH2R140Q, KDM5CC1247X, MPLP565L, MPLW515L,
NPM1A249G, NRASG12V
PMF_10 3 CASP2D169G, HINT1D68G, SMAD2M411V
PMF_11 4 ATICL384P, C9orf102N534S, NOVA2A464V, RBBP6T1711A
PPV_1 2 JAK2V617F, STK11M127R
PPV_2 10 BARD1G203EfsX10, CHD5D1271N, CUX1E1065G, DNASE1V237A, DUSP6D124G, JAK2V617F, NF1G2103R,
NF1P1706R, NOTCH1R1279H, PRDM2C1195X
PPV_3 3 JAK2V617F, TET2R550X, TMEM115G7D
PPV_4 7 CBLD460delD, DAP3G5E, GOLGA5S115fsX3, JAK2V617F, MTUS1P1077fsX20, NCOA1P204S, SCRIBH1217P
PPV_5 7 BRCA2D1540G, IP6K2G28R, JAK2V617F, MGMTP15S, NTRK1Y72H, POLII261M, XRCC4E121V
PV_1 4 FAT4R175L, JAK2V617F, RAG2S111P, RBM15R703G
PV_2 1 JAK2V617F
PV_3 21 ABL2E362G, BARD1K415R, C11orf30E916G, DLGAP2P572fsX72, FAT1G610R, FAT4T3251A, JAK2V617F,
MAD1L1R54G, MECOMF522S, MLLD251G, MYH9F117L, NINV2041A, PARP4D1547G, POLEF2063L, POLKS832N,
PRDM1L414P, RAD54BG758S, RAG2S368P, TSG101I128V, UIMC1K6R, VBP1D191G
PV_4 6 BRD4E49fsX42, JAK2V617F, LIG3A836T, POLKT405I, PTPRGV426M, XAB2E26K
PV_5 7 APCA2128V, CBFA2T3C169Y, JAK2V617F, PPP2R1BG161D, PTPN23P1099S, ST5L636fsX7, STK11M127R
PV_6 5 BRD3T250A, JAK2V617F, MKL1G473R, NF1G2103R, NOTCH1R1279H
PV_7 7 DPH1S311P, HOXA11M294fsX23, JAK2V617F, PARP3M216V, ROBO1D195G, TET2R550X, TMEM115G7D
PV_8 6 CARSK482R, CSNK1EN172D, JAK2V617F, PTPN14W324X, SCRIBH1217P, XRCC1G188R
PV_9 11 APTXC286fsX1, EP300M1470fsX2, FAT2G3691R, JAK2V617F, METV1247A, MLL3A2456T, MYH11K1761R,
MYST3G443S, POLGA154T, POLII261M, XRCC4E121V
Figure 3. Heatmap of the found known variants and of genes
presenting one or more variants in two or more patients in the data
set. The horizontal axis presents the sequenced complete dataset of
patients, with the PV samples grouped on the left, the evolution to
post-PV MF patients (PPV) in the center and the PMF on the right.
The vertical axis illustrates the recurrently mutated gene as
exemplified in the legend.
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reliable germline control for identifying true somatic mutations in
MPN. We set up an analysis pipeline using the most stringent
procedure to avoid false-positive calls of somatic mutations.
In particular, paired germline and somatic DNA samples of the
learning dataset were sequenced for reaching the same fold
coverage. Moreover, we called somatic only those variants with no
reads both in the paired germline DNA and in any other germline
sample of the cohort. To these stringent ‘somatic’ ﬁlters, two
additional controls were added to discard any possible
polymorphisms (only variants with a frequency o1% in the
1000 genomes database were retained) as well as possible benign
mutations (only non-synonymous variants were retained). Finally,
all ﬁltered variants were annotated with the functional effect
prediction of ﬁve different algorithms.
Using this multistep bioinformatics pipeline, we ﬁnally identi-
ﬁed 141 ‘genuine’ somatic non-synonymous mutations affecting
121 genes and 5 miRNAs that were then tested for recurrence in a
larger cohort of 189 patients. The variants found in the SCRIB,
MIR662, BARD1, TCF12, FAT4, DAP3, POLG and NRAS genes were
recurrent with a frequency higher than 3%. In particular, SCRIB,
MIR662 and BARD1 showed frequencies of 7.9, 7.4, and 5.3%,
respectively, which were higher than those described for some
well-known mutational hotspots.18
Some ﬁndings appear to join some of these genes, suggesting
the potential role of these genes in the pathogenesis of MPN.
SCRIB and FAT4 are two proteins that regulate planar cell polarity
differentiation. SCRIB encodes a cytoplasmic scaffolding
protein consisting of leucine-rich repeats and PDZ domains that
regulates protein–protein interactions,24 while FAT4 belongs to
the E-cadherin family and may control noncanonical Wnt/planar
cell polarity signaling;25 both pathways play a crucial role in the
regulation of polarity and tissue homeostasis. Interestingly, TCF12
protein, also known as HEB, could be linked with this pathway.
TCF12 forms heterodimers with other bHLH E-proteins and with
chimeric protein AML1-ETO26–28 and works as a transcriptional
repressor of E-cadherin, thus playing an important role in cancer
cell progression by enhancing the epithelial–mesenchymal
transition process.29 The endothelial-mesenchymal transition is a
form of the more widely known epithelial–mesenchymal transi-
tion; similarly to epithelial–mesenchymal transition, endothelial-
mesenchymal transition can be induced by transforming growth
factor-b and allows a polarized cell, which normally interacts with
Table 3. Somatic mutations in microRNAs coding regions
miRNA ID Chromosome SNP Variant_effect miRNA location Region
MIR662 chr16:820215 rs74656628 T4A p.T924S MSLNL gene Pre-miRNA
MIR17 chr13:92002884 unknown A4G intergenic Mature sequence hsa-miR-17-5p
MIR19A chr13:92003195 unknown T4C intergenic Pre-miRNA
MIR542 chrX:133675465 unknown C4T intergenic Pre-miRNA
MIR663A chr20:26188912 rs7266947 A4C intergenic Pre-miRNA
Table 4. Recurrent mutations in the validation dataset
Chromosome Reference
nucleotide
Variant Gene AA
Change
Pathology
(PV|PPV|PMF)
Freq (PV|PPV|PMF) Freq
tot
PV
thrombotic
risk
(Low|High)
PPV-PMF IPSS
(Low|Int-1|Int-
2|High|Unknown)
chr9 G T JAK2 V617F 50|48|72 100.00|100.00|79.12 90.0 14|36 17|33|41|21|8
chr8 T G SCRIB H1217P 5|5|5 10.00|10.42|5.49 7.9 2|3 1|1|4|4|0
chr16 T A MIR662 2|6|6 4.00|12.50|6.59 7.4 1|1 2|1|6|3|0
chr2 C G BARD1 C557S 1|3|6 2.00|6.25|6.59 5.3 1|0 2|3|1|3|0
chr4 G T FAT4 R175L 2|2|3 4.00|4.17|3.30 3.7 0|2 0|2|1|1|1
chr15 G A TCF12 G300S 1|2|4 2.00|4.17|4.40 3.7 1|0 0|1|2|3|0
chr1 G A DAP3 G5E 3|1|2 6.00|2.08|2.20 3.2 0|3 1|0|1|1|0
chr1 C A NRAS G12V 0|0|3 0.00|0.00|3.30 1.6 0|0 0|0|1|2|0
chr15 C T POLG A154T 1|2|0 2.00|4.17|0.00 1.6 0|1 1|1|0|0|0
chr8 G T RECQL4 P879H 0|1|1 0.00|2.08|1.10 1.1 0|0 0|0|1|1|0
chr10 C A AIFM2 G2V 1|1|0 2.00|2.08|0.00 1.1 1|0 0|0|0|1|0
chr3 C T PTPN23 P1099S 1|0|1 2.00|0.00|1.10 1.1 0|1 0|1|0|0|0
chr2 G A DNMT3A R693C 0|0|2 0.00|0.00|2.20 1.1 0|0 0|2|0|0|0
chr3 C T TMEM115 G7D 0|1|0 0.00|2.08|0.00 0.5 0|0 1|0|0|0|0
chr5 A T XRCC4 E121V 0|1|0 0.00|2.08|0.00 0.5 0|0 0|1|0|0|0
chr17 G A NF1 G2103R 0|1|0 0.00|2.08|0.00 0.5 0|0 0|1|0|0|0
chr4 C T TET2 R550X 0|1|0 0.00|2.08|0.00 0.5 0|0 1|0|0|0|0
chr17 C G NF1 P1706R 0|1|0 0.00|2.08|0.00 0.5 0|0 0|1|0|0|0
chr16 C T MPG R55C 0|0|1 0.00|0.00|1.10 0.5 0|0 0|1|0|0|0
chr8 C T MYST3 G443S 0|0|1 0.00|0.00|1.10 0.5 0|0 0|0|1|0|0
chr15 C T IDH2 R140Q 0|1|0 0.00|2.08|0.00 0.5 0|0 1|0|0|0|0
chr1 T C RFWD2 M299V 0|0|1 0.00|0.00|1.10 0.5 0|0 0|1|0|0|0
chr19 C CG BRD4 E49fsX42 0|0|1 0.00|0.00|1.10 0.5 0|0 0|0|1|0|0
chr5 G A POLK S832N 0|0|1 0.00|0.00|1.10 0.5 0|0 0|0|1|0|0
chr7 T C MAD1L1 R54G 1|0|0 2.00|0.00|0.00 0.5 1|0 0|0|0|0|0
chr22 C T MKL1 G473R 0|1|0 0.00|2.08|0.00 0.5 0|0 0|1|0|0|0
chr1 G T MPL W515L 0|0|1 0.00|0.00|1.10 0.5 0|0 0|0|1|0|0
chr1 T G PDE4DIP I303L 0|0|2 0.00|0.00|2.20 1.06 0|0 0|1|0|1|0
chr1 G T NTRK1 G613V 7|4|7 14.00|8.33|7.69 9.52 2|5 2|2|5|1|1
chr16 T G ZFHX3 T428P 1|0|1 2.00|0.00|1.10 1.06 1|0 0|0|1|0|0
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the basement membrane via its basal surface, to undergo multiple
changes that enable it to assume a mesenchymal cell phenotype,
which includes enhanced migratory capacity, invasiveness,
elevated resistance to apoptosis and an increased ability to
induce ﬁbrosis. Interestingly, endothelial-mesenchymal transition
and the resulting endothelial cell fate have been recently
implicated in the pathogenesis of PMF.30–32
The SCRIBH1217P variant is a missense mutation predicted to be
damaging via SIFT and PolyPhen2. In particular, missense
mutations in the same SCRIB c-terminal domain region signiﬁ-
cantly disrupt the membrane subcellular localization of the
protein, and this was suggested to be one possible pathogenic
mechanisms for planar cell polarity alterations in mammals.33,34
Similarly, the FAT4R175L mutation is located in the extracellular
cadherin domain, and Polyphen2 together with MutationTaster
were used to reveal that this FAT4 mutation is predicted
to adversely affect protein function and alter the planar cell
polarity environment. Furthermore, studies in Drosophila and
mammalian cell lines have shown that SCRIB loss and
RAS activation cooperate (interclonally or intraclonally) to
promote invasion.35–37 In Drosophila, interclonal cooperation in
RasV12 and Scrib-minus tumor clones revealed a two-level
mechanism in which Scrib-minus cells promote the neoplastic
development of RasV12 cells. Speciﬁcally, this mechanism involves
(1) the spread of stress-induced JNK activity from scrib-minus cells
to RasV12-activated cells followed by (2) the expression of JAK/
STAT-activating cytokines downstream of JNK.38
Further insights into the molecular and pathogenetic complex-
ity of MPN emerged from the discovery of BARD1, POLG and
DAP3 mutations. All three of these variants are predicted to be
damaging, and while DAP3 and POLG are mitochondrial proteins
involved in DNA repair and apoptosis pathways,39,40 BARD1 is a
nuclear BRCA1-independent mediator between genotoxic stress
and p53-dependent apoptosis41 (see the Discussion section of the
Supplementary Information for details).
In addition to above considerations, we were intrigued by the
fact that the two PMF patients in the learning cohort showing
the NRASG12V mutation presented a rapid progression into
an accelerated form of the disease. Therefore, we attempted
to validate this association in an additional 66 PMF cases,
composing a ﬁnal cohort of 168 PMF. Moreover, because NRAS
and KRAS mutations have been described as potentially mutually
exclusive,42,43 we tested this additional cohort for KRAS mutations
to verify mutual exclusivity. We found that 4.7% of the
PMF patients harbored a heterozygous NRAS mutation in codon
12. Conceivably, considering all the 8 NRAS mutated patients all
together, we found that this mutation was associated with a
poorer prognosis as supported by the fact that the 8 patients
clustered in the intermediate-2 and high-risk category of the
DIPSS-plus score. Only 2% of all PMF patients harbored
heterozygous KRAS mutations (G12R, G12S and G13D), while the
co-occurrence of NRASG12V and KRASG13D or JAK2V617F
mutations was observed only for a single patient (we were
unable to determine whether the two mutations arose from the
same or different clone since frozen cell samples were not
available for this patient). The low number of patients harboring
KRAS mutations alone, precluded any meaningful analysis of the
association with disease progression. Overall, these data suggest
that NRAS mutations speciﬁcally associate with a poorer outcome,
although the molecular mechanism remains to be investigated.
Mutations in microRNAs warrant a separate discussion. Even if
additionally speciﬁc studies are necessary to support a functional
role of the MIR662 variant rs74656628, some interesting features
are worth mentioning. The human MIR662 is an intragenic
microRNA that resides in a non-coding exon sequence of the
mesothelin-like gene. This is a heterozygous missense mutation
that occurs in the precursor sequence of the micro-RNA.38
A bioinformatics prediction analysis run with the In-Silico-Dicer
and RNAFold suggested that this mutation could modify the RNA
secondary structure and lead to the production of a different
mature miRNA (see Supplementary Information for details).
In summary, this NGS study presents new data that contribute
to elucidating the very high genomic complexity in MPN disorders
and identiﬁes new variants in cancer-related genes that are
potentially involved in the pathogenesis of the disease and may
deserve further studies.
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Table 5. Clinical features of PMF patients screened for NRAS mutations
Variables NRAS WT (n¼ 160) NRAS mutated (n¼ 8) P
Follow-up, months; median (range) 35.6 (3.01–145.72) 28.0 (4.03–275.57) ns
Age in years; median (range) 66 (19–90) 64 (48–84) ns
Males (%) 109 (68.1%) 6 (75%) ns
Hemoglobin, g/dL; median (range) 12.0 (5.0–16.0) 11.5 (10.0–13.0) ns
Leukocytes,  109/L; median (range) 10.5 (3.0–20.0) 9.8 (1.4–99.6) ns
Platelets,  109/L; median (range) 274 (19–1563) 287 (90–738) ns
Constitutional symptoms; n (%) 85 (53.1%) 7 (87.5%) 0.044
Circulating blasts X1%; n (%) 35 (21.8%) 4 (57.1%) ns
Cytogenetic categories; n (%)a ns
Abnormal 48 (48%) 4 (50%)
Unfavorable karyotype 15 (15%) 2 (25%)
DIPSS-plus risk group; n (%) 0.022
Low 16 (10%) 0
Intermediate- 1 49 (30.6%) 0
Intermediate- 2 65 (40.6%) 6 (75%)
High 30 (18.8%) 2 (25%)
Palpable spleen; n (%) 98 (61.2%) 4 (50%) ns
JAK2V617F; n (%) 96 (60%) 1 (12.5%) 0.001
Progression to acute leukemia; n (%) 12 (7.5%) 0 ns
Dead for disease progression; n (%) 49 (30.6%) 5 (62.5%) 0.043
aEvaluated on available data (n¼ 100/160 for RAS wild-type and 8/8 for RAS mutated. Abbreviations: DIPSS-plus, dynamic international prognostic scoring
system-plus; IPSS, international prognostic scoring system.
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